Why is proteinuria such an important risk factor for progression in clinical trials?

Kidney International, Supplement

Volumn 51, Issue 63, 1997, Pages

  Jerums, G ^a   Panagiotopoulos, S ^a   Tsalamandris, C ^a   Allen, T J ^a   Gilbert, R E ^a   Comper, W D ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Albumin excretion rate; Clinical trials; Diabetic nephropathy; Progression; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; METOPROLOL; NIFEDIPINE; PERINDOPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK FACTOR; URINARY EXCRETION; ALBUMINURIA; PATHOLOGY; REVIEW;

ALBUMINURIA; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; PROTEINURIA; RISK FACTORS;

EID: 0031445910     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)